While EGFRm NSCLC as a whole demonstrates poor sensitivity to ICIs, specific DDR‐related gene signatures may help identify subsets of EGFR‐mutant patients who could derive benefit from immunotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.